Retrospective Analysis of the effect of Chemotherapy on Neutrophil counts and analyse the effect of G-CSF when used in Breast Cancer Patients

preethi's picture
By preethi - 10/31/2009
in
Author(s):
3
Your rating: None Average: 3 (12 votes)

Breast cancer is second leading cause of death in women between ages 45 and 75. Chemotherapy induced neutropenia is a major complication in the treatment of cancer and common side effect. Neutropenia haematopoietic growth factor like G-CSF are used, that stimulates common stem cells in the bone marrow and thus optimizes the patients host defense and decrease the episodes of febrile neutropenia a, hospitalization & number of days on antibiotics treatment.

We analyzed 61 patients who were presented at Curie cancer of Oncology between 2001-2005. Median age of the patient was 52 Years with 19 patients were being prescribed with G-CSF drug and treatment given as and when required after each-chemotherapy and remaining 42 patients were without G-CSF support. The results indicate that the use of G-CSF after the cycle of chemotherapy can be beneficial in controlling chemotherapy-inducing neutropenia.

Author profile page link : http://www.pharmainfo.net/preethireddy

Co-author profile page link : http://www.pharmainfo.net/ismailpasha

Click to see next slide

<!--[if gte IE 7]>--> <!--<![endif]-->

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

<!--[if gte IE 7]>--> <!--<![endif]-->

Suhaas's picture

Questions

Submitted by Suhaas on Sun, 11/22/2009 - 07:07.
3

1. Apart from retrospective analysis, what are the other sorts of analysis?
2. Apart from the 2 parameters you mentioned, what are the other parameters for monitoring the breast cancer?
3. Many parameters alter the neutrophil count, then how can these changes in neutrophil count be correlated to breast cancer?

Suhaas

Bairwa Vishal Phoolsingh's picture

Pharmcogenomic variations & patient selection

Submitted by Bairwa Vishal P... on Sat, 11/21/2009 - 17:16.
3

Hello Ms. Preeti,

My question is in reference to the G-CSF usage and associated variations in the breast cancer patients. Whether the patients you have selected for the study are they are evaluated on the basis of pharmacogenomic criterias because the variations may be influnced by the genetic difference also....
And secondly I wannna know that why u have choosen the G-CSF only means what is the influnencing or the supportive data for its appropriate selection.

Thankyou...

Y mahalaxmi's picture

Hi preethi, 1.Why females in

Submitted by Y mahalaxmi on Sat, 11/21/2009 - 11:25.
3

Hi preethi,

1.Why females in urban area are more susceptible to breast cancer than females in rural area?

Y Mahalaxmi
http://www.pharmainfo.net/y-mahalaxmi

shobha deepthikompella's picture

hello

Submitted by shobha deepthik... on Fri, 11/20/2009 - 16:02.
1

can you tell me what are the other methods used to carry out the neutrophilic counting??

Shobha Deepthikompella
http://www.pharmainfo.net/shobhadeepthi

Ritesh Bajaj 's picture

query

Submitted by Ritesh Bajaj on Sat, 11/14/2009 - 11:49.
3

hi,

Addition of granulocyte-colony stimulating factor (G-CSF) may further increase chemosensitive state in premenopausal node-positive breast cancer patients with induced angiogenesis after surgery. How?

Bhawna Khurana's picture

HI, You might have heard

Submitted by Bhawna Khurana on Sat, 11/14/2009 - 11:44.
3

HI,

You might have heard about Paget's disease of the breast...? Is 'G-CSF' useful for the treatment of same?

Jithan Aukunuru's picture

Hospital!!

Submitted by Jithan Aukunuru on Sat, 11/14/2009 - 01:09.
3

Details of the hospital where the study was conducted is not provided I guess? Why was some times chisquare test performed and why was some times t-test performed in the data evaluation?

KINJAL B. RATHOD's picture

Query

Submitted by KINJAL B. RATHOD on Fri, 11/13/2009 - 15:25.
3

Hello,

nice presentation.
ya I also have done work on G CSF which is also use in leukemia patients after chemotherapy.

I want to know Are there any toxicology issues related with G CSF in Breast cancer patients???

regards.

KINJAL B. RATHOD
http://www.pharmainfo.net/kinjal

Dr. T.E.G.K. Murthy's picture

High standard deviations in experimental values

Submitted by Dr. T.E.G.K. Murthy on Thu, 11/12/2009 - 07:56.
3

1. Can we use the concept of chrono pharmacokinetics in the management of breast cancer?

2. What are the permitted SD deviation values to confirm the reproducibility of the method?

3. Whether one was or two way “T” test is conducted in this research.

4. How you can confirm the variations are due to the difference in control and experimental group as it may also attributed by the differences existing in between subjects.

Dixon Thomas's picture

Solution for the color polusion

Submitted by Dixon Thomas on Fri, 11/06/2009 - 02:39.
4

Dear preethi
Nice evidence listed on an important topic. Do you have a solution for the color polusion. I heard like bright red is a vibrant color and that can be very agitating to the mind. Vibrant colors are not used in hospitals that it affect the peace of mind of patients do you have a comment on the same?

Mr. Dixon Thomas, M. Pharm, M. S., RPh
http://www.pharmainfo.net/pharmacistdixon

Bhasker's picture

Possibility of raising immunity with factors (GM-CSF & G-CSF)

Submitted by Bhasker on Wed, 11/04/2009 - 04:27.
3

Dear Preethi,
I have the following questions:
We are prone to develop antibodies against GM-CSF when administered thus neutralizing its effects.What is the rationale in using GM-CSF?
2.Though we have other immune stimulants why we have to restrict only to GM-CSF or G-CSF?
3.Also if there is a possibility of raising immunity with these factors(GM-CSF & G-CSF) what is the limitation in their use in AIDS infection?

Bhasker
http://www.pharmainfo.net/bhasker